Decrease in the frequency of treatment for patent ductus arteriosus after implementation of consensus guidelines: a 15-year experience

J Perinatol. 2019 Nov;39(11):1569-1576. doi: 10.1038/s41372-019-0432-8. Epub 2019 Jul 23.

Abstract

Background: Patent ductus arteriosus (PDA) management varies widely among neonatologists.

Local problem: Lack of institution-specific evidence-based guidelines for therapeutic closure of PDA.

Methods: Quality improvement project among infants <30 weeks gestational age (GA) designed to determine whether the odds of therapy for closing the PDA, adjusted for GA, decreased after implementing evidence-based guidelines.

Intervention: Implementation of guidelines with conservative approach to PDA management.

Results: The frequency of PDA treatment decreased from 446/1125 (40%) in Epoch 1 to 96/482 (20%) in Epoch 2. PDA treatment was more frequent in neonates 23-26 weeks GA than those of 27-29 weeks GA (43% vs. 28%, respectively). Among 542 infants receiving indomethacin for PDA, 25% had subsequent ligation; the odds of ligation after indomethacin were lower in neonates 27-29 weeks GA and decreased during Epoch 2.

Conclusions: The frequency of medical and surgical treatment for therapeutic closure of PDA decreased after implementing evidence-based treatment guidelines.

MeSH terms

  • Cardiac Surgical Procedures / statistics & numerical data*
  • Consensus
  • Cyclooxygenase Inhibitors / therapeutic use
  • Disease Management
  • Ductus Arteriosus, Patent / therapy*
  • Female
  • Gestational Age
  • Guideline Adherence*
  • Humans
  • Indomethacin / administration & dosage
  • Infant, Newborn
  • Infant, Premature
  • Intensive Care Units, Neonatal
  • Ligation
  • Logistic Models
  • Male
  • Quality Improvement*
  • Texas
  • Time-to-Treatment*
  • Treatment Failure

Substances

  • Cyclooxygenase Inhibitors
  • Indomethacin